Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.34-$3.41 to $3.28-$3.32 vs $3.36 Est; Lowers FY2026 Sales Guidance from $21.479B-$21.780B to $21.178B-$21.379B vs $21.562B Est

Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.34-$3.41 to $3.28-$3.32 vs $3.36 analyst estimate. Lowers FY2026 sales outlook from $21.479 billion-$21.780 billion to $21.178 billion-$21.379 billion vs $21.562 billion estimate.